Centrally  ||| S:0 E:10 ||| FW
administered  ||| S:10 E:23 ||| FW
isoproterenol  ||| S:23 E:37 ||| FW
induces  ||| S:37 E:45 ||| FW
sympathetic  ||| S:45 E:57 ||| FW
outflow  ||| S:57 E:65 ||| FW
via  ||| S:65 E:69 ||| FW
brain  ||| S:69 E:75 ||| FW
prostaglandin  ||| S:75 E:89 ||| FW
E2-mediated  ||| S:89 E:101 ||| FW
mechanisms  ||| S:101 E:112 ||| FW
in  ||| S:112 E:115 ||| FW
rats  ||| S:115 E:120 ||| FW
Brain  ||| S:120 E:126 ||| FW
β-adrenoceptor  ||| S:126 E:141 ||| FW
stimulation  ||| S:141 E:153 ||| FW
can  ||| S:153 E:157 ||| MD
induce  ||| S:157 E:164 ||| VB
elevations  ||| S:164 E:175 ||| VBN
of  ||| S:175 E:178 ||| IN
plasma  ||| S:178 E:185 ||| JJ
levels  ||| S:185 E:192 ||| NNS
of  ||| S:192 E:195 ||| IN
noradrenaline ||| S:195 E:208 ||| NN
.  ||| S:208 E:210 ||| .
However ||| S:210 E:217 ||| RB
,  ||| S:217 E:219 ||| ,
there  ||| S:219 E:225 ||| EX
have  ||| S:225 E:230 ||| VBP
been  ||| S:230 E:235 ||| VBN
no  ||| S:235 E:238 ||| DT
detailed  ||| S:238 E:247 ||| JJ
studies  ||| S:247 E:255 ||| NNS
related  ||| S:255 E:263 ||| VBN
to  ||| S:263 E:266 ||| TO
signaling  ||| S:266 E:276 ||| VB
pathways  ||| S:276 E:285 ||| JJ
downstream  ||| S:285 E:296 ||| NN
of  ||| S:296 E:299 ||| IN
β-adrenoceptors  ||| S:299 E:315 ||| JJ
responsible  ||| S:315 E:327 ||| JJ
for  ||| S:327 E:331 ||| IN
central  ||| S:331 E:339 ||| JJ
sympathetic  ||| S:339 E:351 ||| JJ
outflow ||| S:351 E:358 ||| NN
.  ||| S:358 E:360 ||| .
In  ||| S:360 E:363 ||| IN
the  ||| S:363 E:367 ||| DT
present  ||| S:367 E:375 ||| JJ
study ||| S:375 E:380 ||| NN
,  ||| S:380 E:382 ||| ,
we  ||| S:382 E:385 ||| PRP
pharmacologically  ||| S:385 E:403 ||| VBP
examined  ||| S:403 E:412 ||| VBN
the  ||| S:412 E:416 ||| DT
possibility  ||| S:416 E:428 ||| NN
that  ||| S:428 E:433 ||| WDT
centrally  ||| S:433 E:443 ||| VBZ
administered  ||| S:443 E:456 ||| VBN
isoproterenol  ||| S:456 E:470 ||| NNS
can  ||| S:470 E:474 ||| MD
induce  ||| S:474 E:481 ||| VB
elevations  ||| S:481 E:492 ||| VBN
of  ||| S:492 E:495 ||| IN
plasma  ||| S:495 E:502 ||| JJ
noradrenaline  ||| S:502 E:516 ||| JJ
levels  ||| S:516 E:523 ||| NNS
in  ||| S:523 E:526 ||| IN
a  ||| S:526 E:528 ||| DT
brain  ||| S:528 E:534 ||| NN
prostaglandin-dependent  ||| S:534 E:558 ||| JJ
manner ||| S:558 E:564 ||| NN
.  ||| S:564 E:566 ||| .
In  ||| S:566 E:569 ||| IN
addition ||| S:569 E:577 ||| NN
,  ||| S:577 E:579 ||| ,
we  ||| S:579 E:582 ||| PRP
also  ||| S:582 E:587 ||| RB
examined  ||| S:587 E:596 ||| VBN
whether  ||| S:596 E:604 ||| IN
or  ||| S:604 E:607 ||| CC
not  ||| S:607 E:611 ||| RB
intracerebroventricular  ||| S:611 E:635 ||| JJ
administration  ||| S:635 E:650 ||| NN
of  ||| S:650 E:653 ||| IN
isoproterenol  ||| S:653 E:667 ||| NNS
could  ||| S:667 E:673 ||| MD
release  ||| S:673 E:681 ||| VB
endogenously  ||| S:681 E:694 ||| FW
synthesized  ||| S:694 E:706 ||| FW
prostaglandin  ||| S:706 E:720 ||| FW
( ||| S:720 E:721 ||| -LRB-
PG ||| S:721 E:723 ||| NNP
)  ||| S:723 E:725 ||| -RRB-
E2  ||| S:725 E:728 ||| CD
in  ||| S:728 E:731 ||| IN
the  ||| S:731 E:735 ||| DT
hypothalamic  ||| S:735 E:748 ||| FW
paraventricular  ||| S:748 E:764 ||| FW
nucleus  ||| S:764 E:772 ||| FW
( ||| S:772 E:773 ||| -LRB-
PVN ||| S:773 E:776 ||| NNP
)  ||| S:776 E:778 ||| -RRB-
by  ||| S:778 E:781 ||| IN
using  ||| S:781 E:787 ||| VBG
the  ||| S:787 E:791 ||| DT
brain  ||| S:791 E:797 ||| NN
microdialysis  ||| S:797 E:811 ||| NN
technique  ||| S:811 E:821 ||| NN
combined  ||| S:821 E:830 ||| VBN
with  ||| S:830 E:835 ||| IN
liquid  ||| S:835 E:842 ||| JJ
chromatography-ion  ||| S:842 E:861 ||| JJ
trap  ||| S:861 E:866 ||| NN
tandem  ||| S:866 E:873 ||| NN
mass  ||| S:873 E:878 ||| NN
spectrometry  ||| S:878 E:891 ||| NNS
( ||| S:891 E:892 ||| -LRB-
LC-ITMS ||| S:892 E:899 ||| NNP
( ||| S:899 E:900 ||| -LRB-
n ||| S:900 E:901 ||| LS
) ||| S:901 E:902 ||| -RRB-
) ||| S:902 E:903 ||| -RRB-
.  ||| S:903 E:905 ||| .
Under  ||| S:905 E:911 ||| IN
urethane  ||| S:911 E:920 ||| JJ
anesthesia ||| S:920 E:930 ||| NN
,  ||| S:930 E:932 ||| ,
a  ||| S:932 E:934 ||| DT
femoral  ||| S:934 E:942 ||| JJ
venous  ||| S:942 E:949 ||| JJ
line  ||| S:949 E:954 ||| NN
was  ||| S:954 E:958 ||| VBD
inserted  ||| S:958 E:967 ||| VBN
for  ||| S:967 E:971 ||| IN
infusion  ||| S:971 E:980 ||| NN
of  ||| S:980 E:983 ||| IN
saline  ||| S:983 E:990 ||| NN
and  ||| S:990 E:994 ||| CC
a  ||| S:994 E:996 ||| DT
femoral  ||| S:996 E:1004 ||| JJ
arterial  ||| S:1004 E:1013 ||| JJ
line  ||| S:1013 E:1018 ||| NN
was  ||| S:1018 E:1022 ||| VBD
inserted  ||| S:1022 E:1031 ||| VBN
for  ||| S:1031 E:1035 ||| IN
collecting  ||| S:1035 E:1046 ||| VBG
blood  ||| S:1046 E:1052 ||| NN
samples ||| S:1052 E:1059 ||| NNS
.  ||| S:1059 E:1061 ||| .
Next ||| S:1061 E:1065 ||| JJ
,  ||| S:1065 E:1067 ||| ,
animals  ||| S:1067 E:1075 ||| NNS
were  ||| S:1075 E:1080 ||| VBD
placed  ||| S:1080 E:1087 ||| VBN
in  ||| S:1087 E:1090 ||| IN
a  ||| S:1090 E:1092 ||| DT
stereotaxic  ||| S:1092 E:1104 ||| JJ
apparatus  ||| S:1104 E:1114 ||| NN
for  ||| S:1114 E:1118 ||| IN
application  ||| S:1118 E:1130 ||| NN
of  ||| S:1130 E:1133 ||| IN
test  ||| S:1133 E:1138 ||| NN
agents ||| S:1138 E:1144 ||| NNS
.  ||| S:1144 E:1146 ||| .
Catecholamines  ||| S:1146 E:1161 ||| NNP
in  ||| S:1161 E:1164 ||| IN
the  ||| S:1164 E:1168 ||| DT
plasma  ||| S:1168 E:1175 ||| NN
were  ||| S:1175 E:1180 ||| VBD
extracted  ||| S:1180 E:1190 ||| VBN
by  ||| S:1190 E:1193 ||| IN
alumina  ||| S:1193 E:1201 ||| JJ
absorption  ||| S:1201 E:1212 ||| NN
and  ||| S:1212 E:1216 ||| CC
were  ||| S:1216 E:1221 ||| VBD
assayed  ||| S:1221 E:1229 ||| VBN
by  ||| S:1229 E:1232 ||| IN
high-performance  ||| S:1232 E:1249 ||| JJ
liquid  ||| S:1249 E:1256 ||| JJ
chromatography  ||| S:1256 E:1271 ||| NN
with  ||| S:1271 E:1276 ||| IN
electrochemical  ||| S:1276 E:1292 ||| JJ
detection ||| S:1292 E:1301 ||| NN
.  ||| S:1301 E:1303 ||| .
Quantification  ||| S:1303 E:1318 ||| NNP
of  ||| S:1318 E:1321 ||| IN
PGE2  ||| S:1321 E:1326 ||| CD
in  ||| S:1326 E:1329 ||| IN
rat  ||| S:1329 E:1333 ||| JJ
PVN  ||| S:1333 E:1337 ||| NNP
microdialysates  ||| S:1337 E:1353 ||| NN
was  ||| S:1353 E:1357 ||| VBD
performed  ||| S:1357 E:1367 ||| VBN
by  ||| S:1367 E:1370 ||| IN
the  ||| S:1370 E:1374 ||| DT
LC-ITMS ||| S:1374 E:1381 ||| JJ
( ||| S:1381 E:1382 ||| -LRB-
n ||| S:1382 E:1383 ||| LS
)  ||| S:1383 E:1385 ||| -RRB-
method ||| S:1385 E:1391 ||| NN
.  ||| S:1391 E:1393 ||| .
We  ||| S:1393 E:1396 ||| PRP
demonstrated  ||| S:1396 E:1409 ||| VBD
that  ||| S:1409 E:1414 ||| IN
centrally  ||| S:1414 E:1424 ||| RB
administered  ||| S:1424 E:1437 ||| VBN
isoproterenol-induced  ||| S:1437 E:1459 ||| JJ
elevations  ||| S:1459 E:1470 ||| NNS
of  ||| S:1470 E:1473 ||| IN
plasma  ||| S:1473 E:1480 ||| JJ
noradrenaline  ||| S:1480 E:1494 ||| NN
could  ||| S:1494 E:1500 ||| MD
be  ||| S:1500 E:1503 ||| VB
mediated  ||| S:1503 E:1512 ||| VBN
via  ||| S:1512 E:1516 ||| IN
activation  ||| S:1516 E:1527 ||| NN
of  ||| S:1527 E:1530 ||| IN
β-adrenoceptors  ||| S:1530 E:1546 ||| JJ
and  ||| S:1546 E:1550 ||| CC
the  ||| S:1550 E:1554 ||| DT
downstream  ||| S:1554 E:1565 ||| FW
phospholipase  ||| S:1565 E:1579 ||| FW
A2-cyclooxygenase  ||| S:1579 E:1597 ||| FW
pathway ||| S:1597 E:1604 ||| FW
.  ||| S:1604 E:1606 ||| .
Furthermore ||| S:1606 E:1617 ||| RB
,  ||| S:1617 E:1619 ||| ,
PGE2  ||| S:1619 E:1624 ||| NNP
in  ||| S:1624 E:1627 ||| IN
the  ||| S:1627 E:1631 ||| DT
PVN  ||| S:1631 E:1635 ||| NNP
and  ||| S:1635 E:1639 ||| CC
the  ||| S:1639 E:1643 ||| DT
PGE2  ||| S:1643 E:1648 ||| CD
receptor  ||| S:1648 E:1657 ||| CD
EP3  ||| S:1657 E:1661 ||| CD
subtype  ||| S:1661 E:1669 ||| NNS
appear  ||| S:1669 E:1676 ||| VBP
to  ||| S:1676 E:1679 ||| TO
play  ||| S:1679 E:1684 ||| VB
an  ||| S:1684 E:1687 ||| DT
important  ||| S:1687 E:1697 ||| JJ
role  ||| S:1697 E:1702 ||| NN
in  ||| S:1702 E:1705 ||| IN
the  ||| S:1705 E:1709 ||| DT
process ||| S:1709 E:1716 ||| NN
.  ||| S:1716 E:1718 ||| .
Our  ||| S:1718 E:1722 ||| PRP$
results  ||| S:1722 E:1730 ||| NNS
suggest  ||| S:1730 E:1738 ||| VBP
that  ||| S:1738 E:1743 ||| IN
central  ||| S:1743 E:1751 ||| JJ
isoproterenol-induced  ||| S:1751 E:1773 ||| JJ
sympathetic  ||| S:1773 E:1785 ||| JJ
outflow  ||| S:1785 E:1793 ||| NN
is  ||| S:1793 E:1796 ||| VBZ
mediated  ||| S:1796 E:1805 ||| VBN
via  ||| S:1805 E:1809 ||| IN
brain  ||| S:1809 E:1815 ||| NN
PGE2  ||| S:1815 E:1820 ||| NN
in  ||| S:1820 E:1823 ||| IN
a  ||| S:1823 E:1825 ||| DT
PGE2  ||| S:1825 E:1830 ||| CD
receptor  ||| S:1830 E:1839 ||| CD
EP3  ||| S:1839 E:1843 ||| CD
subtype-dependent  ||| S:1843 E:1861 ||| JJ
manner ||| S:1861 E:1867 ||| NN
.  ||| S:1867 E:1869 ||| .
